Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Drugs under Simultaneous Global Development May also Be Eligible for New Fast-Track Review System: MHLW Exec
June 26, 2014
-
ACADEMIA Univ. Says Data Leaks in SIGN Run Afoul of Personal Information Law, Newly Finds Bristol’s Misconduct
June 25, 2014
-
BUSINESS Plavix Grabs Top Spot in FY2013 Domestic Ethical Drug Sales Ranking
June 24, 2014
-
BUSINESS Probe Finds Takeda’s Systematic Involvement in CASE-J Study, No Data Tampering
June 23, 2014
-
REGULATORY First Generics of Diovan, Blopress AGs Join Reimbursement List
June 20, 2014
-
BUSINESS Takeda Ceases Development of TAK-700 for Prostate Cancer on Lackluster PIII Results
June 20, 2014
-
BUSINESS Japan Vaccine President and Chairman Swap Posts
June 19, 2014
-
REGULATORY LDP Members Request Govt to Stay with Current Biennial NHI Price Revision
June 18, 2014
-
BUSINESS Sawai Seeks US Approval for Livalo Generic, Submits ANDA
June 17, 2014
-
ORGANIZATION Japan Diabetes Group Announces Recommendations on Proper Use of SGLT-2 Inhibitors
June 17, 2014
-
REGULATORY “Annual” NHI Price Revision Erased from Gov’t Draft Policy Blueprint
June 16, 2014
-
BUSINESS AZ to Shuffle Sales, Marketing Units, Focus on 3 Disease Areas
June 16, 2014
-
BUSINESS Takeda Debuts Aspirin-PPI Combination Drug Takelda in Japan
June 13, 2014
-
REGULATORY LDP Members with Vested Interests Slam Annual NHI Price Revision
June 12, 2014
-
BUSINESS Nippon Shinyaku to Concentrate Sales Force in Three Therapeutic Fields
June 11, 2014
-
REGULATORY Ex-Novartis Employee Nabbed over Diovan Data Tampering: Reports
June 11, 2014
-
REGULATORY Govt Tilting Toward Etching Annual NHI Price Revision in Fiscal Blueprint
June 10, 2014
-
ORGANIZATION Generic Versions of Combination Drug Exforge to Be Named “Amvalo”: JSGM
June 10, 2014
-
REGULATORY Researchers Aiming to Craft Guide for Ultra-Orphan Drug Development
June 9, 2014
-
REGULATORY MHLW, Pharma Officials Take to Nagata-cho in Crusade against Yearly NHI Price Revision
June 6, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…